2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Breast Neoplasms
15
Prostatic Neoplasms
10
Neoplasms
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Leukemia, Myeloid, Acute
4
Triple Negative Breast Neoplasms
3
Ovarian Neoplasms
3
Myelodysplastic Syndromes
3
Endometrial Neoplasms
3
Colorectal Neoplasms
3
Colonic Neoplasms
3
Cardiovascular Diseases
3
Cardiotoxicity
3
Rectal Neoplasms
2
Polycystic Ovary Syndrome
2
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Leukemia
2
Kidney Neoplasms
2
Heart Failure
2
Head and Neck Neoplasms
2
Glioblastoma
2
Endometrial Hyperplasia
2
Carcinoma, Renal Cell
2
Waldenstrom Macroglobulinemia
1
Venous Thrombosis
1
Urogenital Neoplasms
1
Smoking
1
Interventions
Standard of Care
8
Surveys and Questionnaires
7
COVID-19 Vaccines
6
Blood Specimen Collection
6
BNT162 Vaccine
6
Specimen Handling
5
2019-nCoV Vaccine mRNA-1273
5
Hydroxychloroquine
4
Surgical Procedures, Operative
3
Practice Guidelines as Topic
3
tocilizumab
2
sotrovimab
2
sinovac COVID-19 vaccine
2
cilgavimab and tixagevimab drug combination
2
Sodium Chloride
2
Pandemic Preparedness
2
Data Collection
2
CVnCoV COVID-19 vaccine
2
COH04S1 COVID-19 vaccine
2
Azithromycin
2
selinexor
1
remdesivir
1
regorafenib
1
proxalutamide
1
palbociclib
1
ogalvibart
1
monalizumab
1
lenzilumab
1
heterologous prime boost COVID-19 vaccination
1
crexavibart
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
COVID-19
×
Atorvastatin
×
Clear all
NCT04904536
2025-04-10
STRONGER
The George Institute
Phase 3
Active not recruiting
190 enrolled